Michael A. Postow, MD, shares advice to community oncologists on managing the side effects of immunotherapy in patients with melanoma.
Michael A. Postow, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, shares advice to community oncologists on managing the side effects of immunotherapy in patients with melanoma.
In many cases, these treatments are life-saving medications, Postow says. However, it is important to recognize when a patient is experiencing side effects from the treatment so that it can be modified in order to best support the patient.
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More